Microfluidic Cell Sorting for Placental Trophoblast Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prenatal diagnostic methods, such as amniocentesis and non-invasive fetal free nucleic acid sequencing, face challenges including high risks of infection, limited detection range, and low acceptability due to invasiveness, with immunomagnetic beads technology having limitations in accuracy and specificity for isolating placental trophoblast cells.
Innovation Solution
A method using flow cytometry or microfluidics to isolate placental trophoblast cells from cervical exfoliated cells by targeting specific antigens with antibody combinations and sorting using a microfluidic cell sorting chip, which allows for simultaneous labeling and sorting of multiple antigens, improving accuracy and specificity, and increasing cell quantity and quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amniocentesis or cordocentesis is used for prenatal diagnosis, then detection reliability is improved, but risk of infection and abortion increases
Solution Approach 1:
The patent uses cervical exfoliated trophoblast cells as an intermediary sample source instead of direct amniotic fluid or fetal blood sampling. These cells can be non-invasively collected from maternal cervical secretions, serving as a mediator that provides fetal genetic material without requiring invasive procedures that carry infection and abortion risks.
Solution Approach 2:
The patent replaces mechanical invasive sampling methods (needle puncture for amniocentesis/cordocentesis) with biological sampling of exfoliated cells. The isolation and identification of trophoblast cells using flow cytometry and specific antibody markers substitutes the mechanical intrusion with a biological marker-based approach that eliminates physical risks to the fetus.
2Object-affected harmful factors
If fetal free nucleic acid sequencing is used for non-invasive prenatal screening, then risk of infection and abortion is reduced, but detection range is limited
Solution Approach 1:
The patent extracts and isolates specific trophoblast cells from mixed cervical exfoliated cells using flow cytometry and specific antibody markers (such as HLA-G, CK7, CK18). This extraction of pure trophoblast cell populations from the complex maternal-cervical cell mixture enables comprehensive genomic analysis that overcomes the limited detection range of conventional fetal free nucleic acid sequencing.
Solution Approach 2:
The patent changes the sampling parameter from analyzing fetal free nucleic acids in maternal blood to analyzing genomic material from isolated trophoblast cells. This parameter change enables detection of a broader range of genetic conditions including single-gene disorders, chromosomal abnormalities, and structural variations that were not detectable by conventional cell-free DNA methods.
3Productivity
If conventional immunomagnetic beads method is used to isolate trophoblast cells, then isolation is achieved, but accuracy and specificity are limited
Solution Approach 1:
The patent segments the isolation process into multiple sequential steps: first isolating trophoblast cells from other cervical exfoliated cells using flow cytometry with specific markers, then further purifying the population using microfluidic devices with magnetic beads. This segmentation of the isolation process into distinct stages with different separation mechanisms achieves both high efficiency and high specificity that neither method could achieve alone.
Solution Approach 2:
The patent employs a composite isolation approach combining flow cytometry (optical/electrical sorting based on cell surface markers) with magnetic bead-based microfluidic sorting. This composite methodology integrates two different separation principles to achieve superior purity and specificity compared to conventional single-method immunomagnetic bead isolation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides non-invasive, early sampling with low risk of infection, higher reliability, and broader genetic disease detection capabilities, enabling the analysis of whole genome nucleic acid samples for comprehensive genetic disease detection.
Implementation Method 1
performing sorting of a cell resuspension incubated in the step (2) by a flow cytometer
Implementation Method 2
identification and sorting of characteristic fluorescence signals
Implementation Method 3
performing fluorescence labeling and microfluidics cell sorting of a cell resuspension incubated in the step (2) by a microfluidic cell sorting chip
Implementation Method 4
performing fluorescence labeling and microfluidics cell sorting
Implementation Method 5
adding a specific antibody to the sample cell suspension for incubation; the specific antibody is an antibody combination corresponding to the specific antigen(s) expressed on the surface of or inside of trophoblast cells
Data Source
Figure 1~1(b)
Figure 2
Figure 3
AI summary
The present invention discloses a method for isolating placental trophoblast cells from cervical exfoliated cells of a pregnant woman. Based on a specific antigen or combination expressed on the surface or inside of specific trophoblast cells, the designed microfluidic sorting chip or flow cytometer is used in the method to perform cell sorting of a cell suspension of a placental trophoblast sample, thus obtaining isolated and purified placental trophoblast cells. Compared with conventional methods, the method of the present invention has the advantages of non-invasively obtaining specimens and good specificity. Moreover, the method causes low risk of infection and abortion, allows earlier sampling time and can achieve the synchronous labeling of a plurality of antigens as well as identification and sorting of characteristic fluorescence signals; and the method has greatly improved accuracy and higher reliability and broader coverage area of detection results. Furthermore, compared with immunomagnetic beads and other technologies, the method can both have the advantages of cell quantity and quality, and the number of cells obtained are larger than other technologies, and good in specificity and sensitivity. Therefore, the method has excellent application values and thus, can be applied in many detection purposes and application scenarios.